We’re In The News

As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.

Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.

Trump’s Rumored FDA Candidate Strikes Nerve

The Hill, December 8, 2016. Against all expert opinion, Jim O’Neill, “a snake oil salesman” with no medical background, is rumored to head the Food and Drug Administration (FDA) in 2017.

Congress Passes Sweeping Health Care Bill

U.S. News & World Report, December 7, 2016. We opposed the 21st Century Cures bill. It passed anyway. Drug and device companies are popping the champagne. Republicans bought off the White House by promising research $$ for pet projects. How will the law affect you?

The FDA Needs to Pull Failed Drugs From the Market

Barrons, December 3, 2016. Some drugs get to market before proving their clinical worth. Why are they still sold after failing later tests? NCHR says the FDA is to blame.

Why the 21st Century Cures Act Could Be Disastrous for Medicine

Spectrum News, December 1, 2016. Why would anyone vote against “cures,” especially “21st century cures?” Here’s why many health policy and consumer advocacy groups — including the National Center for Health Research — strongly oppose the bill and are asking senators not to pass the bill next week.

Cancer Drugs May Remain Approved Despite Lack of Benefit

Reuters, December 1, 2016. Researchers evaluated studies done on 18 cancer drugs approved between 2008 and 2012 by the FDA. None of the drugs had been found to prolong life, and only one had enough evidence to say it improved quality of life. Yet, all but one retained its approval status.